NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its third-quarter revenues jumped 68 percent year over year on sales of its MaterniT21 Plus laboratory-developed test.

The San Diego-based firm brought in total revenues of $22.9 million for the three months ended Sept. 30, up from $13.6 million for the third quarter of 2011 but falling shy of the consensus Wall Street estimate for revenues of $23.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.